Risk factors for leukemic transformation in patients with primary myelofibrosis.

The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.

Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.

New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.

Choosing between stem cell therapy and drugs in myelofibrosis.

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Extramedullary hematopoiesis.

Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis.

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.